News
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...
2d
News-Medical.Net on MSNSemaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial showsA phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.
While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...
8h
Verywell Health on MSNWegovy vs. Ozempic: Which Is the Better Weight Loss Drug?Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies. Compare side effects here.
Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.
13h
Pharmaceutical Technology on MSNNovo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demandShares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results